Initial experience with MR-guided adaptive spinal stereotactic radiotherapy: a new indication for the MR-linac
Strahlentherapie und Onkologie · 2025
DOI: 10.1007/s00066-025-02401-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Strahlentherapie und Onkologie, 2025. Verfasst von Neris Dincer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Acıbadem MAA University School of Medicine, 34450, Istanbul, Turkey. Hauptthemen laut MEDLINE: Radiosurgery, Spinal Neoplasms, Radiotherapy, Image-Guided, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Acibadem Mehmet Ali Aydinlar University.
Abstract (Originalsprache)
Background and purpose Stereotactic body radiotherapy (SBRT) is associated with good local control and symptom relief in the management of spinal metastases. Delivery of ablative doses and re-irradiation is challenged by spinal cord toxicity. We hypothesized that lower spinal cord doses as well as better target coverage could be yielded with stereotactic magnetic resonance-guided adaptive radiotherapy (SMART). Materials and methods Institutional records were reviewed to retrieve patients who received online MR-guided SBRT for spinal metastases. Each fraction was reviewed to determine the necessity of adaptive planning, to identify reasons for violations that required adaptive planning, and to assess the spinal cord dose. The study also evaluated how adaptive planning contributed to reducing spinal cord doses.
Results
A total of 34 patients with 61 lesions were included. The treatment intent was definitive for 47 (77.1%), palliative for 12 (19.7%), and postoperative for two (3.3%) lesions. The median prescribed Biological Equivalent Dose (BED) 10 was 51.3 Gy. Treatment plans often required adaptive adjustments (81.8%). Adaptive planning significantly improved target coverage (median PTV coverage 92.75% vs. 95%; p < 0.001) and reduced spinal cord D max (median spinal cord D max constraint: 7.3 Gy, median predicted spinal cord D max : 7.76, and median adaptive spinal cord D max 6.18; p < 0.001). Lesion-based median follow-up from irradiation was 7.5 months (range: 1–46 months). One-year LPFS was 94.3%. Six lesions progressed and none of the progressed lesions received a dose above the median BED 10 of 51.3 Gy.
Conclusion
Herein we present our institutional experience with SMART for spinal bone metastases. According to our results, adaptive planning yields better target coverage as well as lower spinal cord doses compared to the predicted plan, which translates into a feasible method for delivering SBRT. Future prospective studies evaluating spinal SMART are awaited.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Acıbadem MAA University School of Medicine, 34450, Istanbul, Turkey.
- Department of Radiation Oncology, Acıbadem Maslak Hospital, Istanbul, Turkey.
- Department of Radiation Oncology, Acıbadem MAA University School of Medicine, 34450, Istanbul, Turkey. banu.atalar@acibadem.com.
ORCID-Profile: Banu Atalar
Förderung
- Acibadem Mehmet Ali Aydinlar University
Zitieren
APA
Dincer, N., Zoto Mustafayev, T., Atahan, C., Gungor, G., Ugurluer, G., Abacioglu, M. U., Ozyar, E., & Atalar, B. (2025). Initial experience with MR-guided adaptive spinal stereotactic radiotherapy: a new indication for the MR-linac. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-025-02401-3
Vancouver
Dincer N, Zoto Mustafayev T, Atahan C, Gungor G, Ugurluer G, Abacioglu MU, et al. Initial experience with MR-guided adaptive spinal stereotactic radiotherapy: a new indication for the MR-linac. Strahlentherapie und Onkologie. 2025. doi:10.1007/s00066-025-02401-3
BibTeX
@article{Dincer2025,
author = {Dincer, Neris and Zoto Mustafayev, Teuta and Atahan, Ceren and Gungor, Gorkem and Ugurluer, Gamze and Abacioglu, Mehmet Ufuk and Ozyar, Enis and Atalar, Banu},
title = {Initial experience with MR-guided adaptive spinal stereotactic radiotherapy: a new indication for the MR-linac},
journal = {Strahlentherapie und Onkologie},
year = {2025},
doi = {10.1007/s00066-025-02401-3}
}
EUVIMED